Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice

          Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice

PR Newswire

HAYWARD, Calif., June 21, 2013

HAYWARD, Calif., June 21, 2013 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH) (the "Company"), a biopharmaceutical company focused on
developing and commercializing products to treat serious diseases associated
with inflammation and autoimmune diseases, today announced that it received a
Staff Determination Letter (the "Notice") on June 19^th, 2013 from the Nasdaq
Stock Market LLC ("Nasdaq").

As previously disclosed, on December 20, 2012, the Nasdaq notified the Company
that the bid price of the Company's listed common stock was not in compliance
with the continued listing requirements due to the bid price closing at less
than $1 per share over the previous 30 consecutive business days. Nasdaq has
determined to remove the Company's common stock from listing and registration
on the Nasdaq Stock Market, at the opening of business on June 28^th, 2013.

The Company plans to appeal the Nasdaq Staff's determination to a Hearings
Panel ("the Panel"). A hearing request will delay the suspension of the
Company's common stock pending the Panel's decision.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include statements about the Company's expectations with respect to
its proposed offering, including its intention to offer and sell shares, its
intention to grant the underwriters an option to purchase additional shares
and its intended use of proceeds from the offering. Such statements are based
on the Company's expectations as of the date of this press release and are
subject to certain risks and uncertainties that could cause actual results to
differ materially, including but not limited to the risks and uncertainties
associated with market conditions and the satisfaction of customary closing
conditions related to the proposed offering, as well as those set forth in the
Company's public filings with the SEC, including the Company's Annual Report
on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form
10-Q for the quarter ended March 31, 2013. The Company disclaims any intent
or obligation to update any forward-looking statements, whether because of new
information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or
510-856-5598.







SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com